American Heart Journal
Volume 155, Issue 1 , Pages 49-55, January 2008

Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial

  • David A. Morrow, MD, MPH

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • These authors contributed equally to this work.
    • Corresponding Author InformationReprint requests: David A. Morrow, MD, MPH, is to be contacted at TIMI Study Group/Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Daniel I. Simon, MD, Division of Cardiovascular Medicine, University Hospitals Case Medical Center, 11100 Euclid Avenue Lakeside 3001, Cleveland, OH 44106.
    • ,
  • Yunmei Wang, PhD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • These authors contributed equally to this work.
    • ,
  • Kevin Croce, MD, PhD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • ,
  • Masashi Sakuma, MD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • ,
  • Marc S. Sabatine, MD, MPH

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Donald W. Reynolds Center for Clinical Cardiovascular Research, Brigham and Women's Hospital, Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Huiyun Gao, MD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • ,
  • Aruna D. Pradhan, MD

      Affiliations

    • Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA
    • ,
  • Aileen M. Healy, PhD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • ,
  • Jacki Buros, BS

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • ,
  • Carolyn H. McCabe, BS

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • ,
  • Peter Libby, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Donald W. Reynolds Center for Clinical Cardiovascular Research, Brigham and Women's Hospital, Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Eugene Braunwald, MD

      Affiliations

    • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Boston, MA
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Daniel I. Simon, MD

      Affiliations

    • Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH
    • Corresponding Author InformationReprint requests: David A. Morrow, MD, MPH, is to be contacted at TIMI Study Group/Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Daniel I. Simon, MD, Division of Cardiovascular Medicine, University Hospitals Case Medical Center, 11100 Euclid Avenue Lakeside 3001, Cleveland, OH 44106.

Received 29 April 2007; accepted 20 August 2007. published online 12 October 2007.

Background

Using a transcriptional profiling approach, we recently identified myeloid-related protein 8/14 (MRP-8/14) to be expressed by platelets during acute myocardial infarction (MI). Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome.

Methods

We performed a nested case-control study (n = 237 case-control pairs) among patients enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial (mean follow-up 24 months) to investigate the risk of cardiovascular death or MI associated with MRP-8/14 measured at 30 days after an acute coronary syndrome.

Results

Patients with cardiovascular death or MI after 30 days (cases) had higher median [25th, 75th percentile] MRP-8/14 levels than patients who remained free of recurrent events (5.6 [2.8, 13.5] mg/L vs 4.0 [1.9, 10.1] mg/L, P = .020). The risk of a recurrent cardiovascular event increased with each increasing quartile of MRP-8/14 (P-trend = 0.007) such that patients with the highest levels had a 2.0-fold increased odds (95% CI 1.1-3.6, P = .029) of a recurrent event after adjusting for standard risk indicators, randomized treatment, and C-reactive protein. Patients with elevated levels of MRP-8/14 and high-sensitivity C-reactive protein showed significantly increased risk of cardiovascular death or MI compared with patients with the lowest levels of both markers (adjusted odds ratio 2.1, 95% CI 1.2-3.8).

Conclusions

Myeloid-related protein 8/14 may be a useful biomarker of platelet and inflammatory disease activity in atherothrombosis and may serve as a novel target for therapeutic intervention.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The PROVE IT-TIMI 22 trial was supported by Bristol-Myers Squibb, Princeton, NJ. Drs Morrow and Sabatine are supported in part by National Institutes of Health grant U01 HL083-1341. This work was also supported in part by grants from the National Institutes of Health (HL57506 and HL60942 to Dr Simon). Dr Pradhan is supported by funding from the National Institutes of Health (HL082740). Dr Libby is supported by research funds from the Leducq Foundation (Paris, France), the Doris Duke Foundation (New York, NY), and the Donald W. Reynolds Foundation (Las Vegas, NV).

PII: S0002-8703(07)00704-1

doi:10.1016/j.ahj.2007.08.018

American Heart Journal
Volume 155, Issue 1 , Pages 49-55, January 2008

Article Tools

* Image Usage & Resolution